Citigroup Maintains Buy on 10x Genomics, Lowers Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Patrick Donnelly maintains a Buy rating on 10x Genomics (NASDAQ:TXG) but lowers the price target from $35 to $23.
October 30, 2024 | 6:33 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup analyst Patrick Donnelly maintains a Buy rating on 10x Genomics but lowers the price target from $35 to $23, indicating a more cautious outlook.
The maintained Buy rating suggests continued confidence in 10x Genomics' potential, but the lowered price target reflects a more cautious outlook, possibly due to market conditions or company performance. This mixed signal may result in neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100